For research use only. Not for therapeutic Use.
SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research[1].
| Catalog Number | I044164 |
| CAS Number | 1628048-93-0 |
| Synonyms | 5-chloro-2-fluoro-N-[4-[4-(4-hydroxycyclohexyl)oxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide |
| Molecular Formula | C23H21ClFN5O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H21ClFN5O4S/c24-14-3-10-19(25)20(11-14)35(32,33)30-15-4-1-13(2-5-15)21-27-22-18(12-26-29-22)23(28-21)34-17-8-6-16(31)7-9-17/h1-5,10-12,16-17,30-31H,6-9H2,(H,26,27,28,29) |
| InChIKey | IKBMUGXVSJZWGW-UHFFFAOYSA-N |
| SMILES | C1CC(CCC1O)OC2=NC(=NC3=C2C=NN3)C4=CC=C(C=C4)NS(=O)(=O)C5=C(C=CC(=C5)Cl)F |
| Reference | [1]. Nis Halland, et al. Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of Osteoarthritis. J Med Chem. 2022 Jan 27;65(2):1567-1584. |
